MacroH2A suppresses the proliferation of the B16 melanoma cell line

Lei,Shaorong; Long,Jianhong; Li,Jiaguang

doi:10.3892/mmr.2014.2482

MacroH2A suppresses the proliferation of the B16 melanoma cell line

Authors:
- Shaorong Lei
- Jianhong Long
- Jiaguang Li
View Affiliations

Affiliations: Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: August 11, 2014 https://doi.org/10.3892/mmr.2014.2482
Pages: 1845-1850

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MacroH2A is the most frequently altered histone, which participates in cancer progression. Increasing evidence demonstrates that cancer progression could be regulated by macroH2A by affecting the cell cycle. In the present study, it was demonstrated that macroH2A suppresses melanoma cell progression and the molecular mechanisms underlying this process were examined. The interference and overexpression vectors of macroH2A were constructed and then transferred into B16 melanoma cells and, following transfection, were analyzed by quantitative polymerase chain reaction (PCR), western blot analysis and immunofluorescence assays. Apoptosis and the cell cycle stage among all the treatment groups were detected. Then, cyclin D1, cyclin D3, cyclin-dependent protein kinase (CDK) 4, CDK6 and CDK8 expression was detected in order to elucidate the effects of macroH2A on cell cycle-related genes. The results demonstrated that the overexpression of macroH2A suppressed melanoma cell progression and arrested the cells in the G2/M stage. Furthermore, macroH2A inhibits cyclin D1, cyclin D2, CDK6 and CDK8 expression in B16 melanoma cells. In conclusion, the results demonstrated that macroH2A, a critical component of chromatin, suppresses the development of melanoma (which results from a disordered cell cycle) through regulating cyclin D1, cyclin D3 and CDK6 genes.

View Figures

View References

1	Portela A and Esteller M: Epigenetic modifications and human disease. Nat Biotechnol. 28:1057–1068. 2010. View Article : Google Scholar : PubMed/NCBI
2	Baylin SB and Jones PA: A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kulaeva OI, Gaykalova DA and Studitsky VM: Transcription through chromatin by RNA polymerase II: histone displacement and exchange. Mutat Res. 618:116–129. 2007. View Article : Google Scholar : PubMed/NCBI
4	Neely KE and Workman JL: The complexity of chromatin remodeling and its links to cancer. Biochim Biophys Acta. 1603:19–29. 2002.PubMed/NCBI
5	Hake SB, Xiao A and Allis CD: Linking the epigenetic ‘language’ of covalent histone modifications to cancer. Br J Cancer. 90:761–769. 2004.
6	Strahl BD and Allis CD: The language of covalent histone modifications. Nature. 403:41–45. 2000. View Article : Google Scholar : PubMed/NCBI
7	Peterson CL and Laniel MA: Histones and histone modifications. Curr Biol. 14:R546–R551. 2004. View Article : Google Scholar : PubMed/NCBI
8	Redon C, Pilch D, Rogakou E, et al: Histone H2a variants H2AX and H2AZ. Curr Opin Genet Dev. 12:162–169. 2002. View Article : Google Scholar : PubMed/NCBI
9	Pehrson JR and Fried VA: macroH2A, a core histone containing a large nonhistone region. Science. 257:1398–1400. 1992. View Article : Google Scholar : PubMed/NCBI
10	Kustatscher G, Hothorn M, Pugieux C, et al: Splicing regulates NAD metabolite binding to histone macroH2A. Nat Struct Mol Biol. 12:624–625. 2005. View Article : Google Scholar : PubMed/NCBI
11	Brooks WH: X chromosome inactivation and autoimmunity. Clin Rev Allergy Immunol. 39:20–29. 2010. View Article : Google Scholar : PubMed/NCBI
12	Chadwick BP and Willard HF: Histone H2A variants and the inactive X chromosome: identification of a second macroH2A variant. Hum Mol Genet. 10:1101–1113. 2001. View Article : Google Scholar : PubMed/NCBI
13	Kapoor A, Goldberg MS, Cumberland LK, et al: The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature. 468:1105–1109. 2010. View Article : Google Scholar : PubMed/NCBI
14	Rickert P, Seghezzi W, Shanahan F, et al: Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene. 12:2631–2640. 1996.PubMed/NCBI
15	Donner AJ, Szostek S, Hoover JM, et al: CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell. 27:121–133. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sánchez I and Dynlacht BD: New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol. 311–321. 2005.PubMed/NCBI
17	Satyanarayana A and Kaldis P: Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 28:2925–2939. 2009. View Article : Google Scholar : PubMed/NCBI
18	Fisher RP: CDKs and cyclins in transition(s). Curr Opin Genet Dev. 7:32–38. 1997. View Article : Google Scholar : PubMed/NCBI
19	Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
20	Andreassi MG: DNA damage, vascular senescence and atherosclerosis. J Mol Med (Berl). 86:1033–1043. 2008. View Article : Google Scholar : PubMed/NCBI
21	Morgan DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 13:261–291. 1997. View Article : Google Scholar : PubMed/NCBI
22	Tyson JJ, Csikasz-Nagy A and Novak B: The dynamics of cell cycle regulation. Bioessays. 24:1095–1109. 2002. View Article : Google Scholar : PubMed/NCBI
23	Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
24	Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
25	Sporn JC, Kustatscher G, Hothorn T, et al: Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene. 28:3423–3428. 2009. View Article : Google Scholar : PubMed/NCBI
26	Novikov L, Park JW, Chen H, et al: QKI-mediated alternative splicing of the histone variant macroH2A1 regulates cancer cell proliferation. Mol Cell Biol. 31:4244–4255. 2011. View Article : Google Scholar : PubMed/NCBI
27	Haugstetter A, Loddenkemper C, Lenze D, et al: Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer. 103:505–509. 2010. View Article : Google Scholar : PubMed/NCBI
28	Buschbeck M and Di Croce L: Approaching the molecular and physiological function of macroH2A variants. Epigenetics. 5:118–123. 2010. View Article : Google Scholar : PubMed/NCBI
29	Zhang R and Adams PD: Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle. 6:784–789. 2007. View Article : Google Scholar : PubMed/NCBI
30	Collado M, Gil J, Efeyan A, et al: Tumour biology: senescence in premalignant tumours. Nature. 436:6422005. View Article : Google Scholar : PubMed/NCBI
31	Dardenne E, Pierredon S, Driouch K, et al: Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol. 19:1139–1146. 2012. View Article : Google Scholar : PubMed/NCBI
32	Shtutman M, Zhurinsky J, Simcha I, et al: The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 96:5522–5527. 1999.
33	Fu M, Wang C, Li Z, et al: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
34	Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582. 1994. View Article : Google Scholar : PubMed/NCBI
35	Gray N, Détivaud L, Doerig C, et al: ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem. 6:859–875. 1999.PubMed/NCBI
36	Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 8:547–566. 2009. View Article : Google Scholar : PubMed/NCBI